Welcome to our dedicated page for Steris Plc news (Ticker: STE), a resource for investors and traders seeking the latest updates and insights on Steris Plc stock.
News and updates about STERIS plc (NYSE: STE) focus on its role as a medical technology company that supports patient care with an emphasis on infection prevention. The company regularly issues press releases from Dublin, Ireland, describing its financial performance, dividends, leadership changes and investor events, giving readers insight into how its healthcare and life science products and services business is developing.
Investors following STERIS news can expect recurring coverage of quarterly and annual financial results, where the company reports total revenue from continuing operations, segment performance for Healthcare, Applied Sterilization Technologies (AST) and Life Sciences, and both GAAP and non-GAAP metrics such as adjusted earnings per diluted share and free cash flow. These releases often include management commentary and an outlook for future fiscal periods, along with detailed explanations of non-GAAP measures.
STERIS news also includes announcements of quarterly dividends, with information on dividend amounts, payment dates and record dates. Some releases highlight the company’s history of dividend growth. Governance and leadership developments, such as transitions in the Chief Financial Officer role or changes to the Board of Directors, are disclosed through both press releases and related SEC filings, and are frequently summarized in the news flow.
In addition, STERIS routinely announces conference calls to discuss financial results, providing access details and replay information for investors and analysts. Each release typically contains a cautionary statement regarding forward-looking information and references to risk factors described in the company’s SEC filings. Readers who monitor this news stream can follow how STERIS communicates its financial performance, strategic outlook, shareholder returns and governance matters over time.
STERIS plc (NYSE: STE) will host a conference call to discuss its fiscal 2023 third quarter financial results on February 9, 2023, at 10:00 a.m. ET. The call will be accessible via the STERIS investor relations website or by phone. A detailed press release regarding the financial results will be issued after the U.S. market closes on February 8, 2023. For those unable to attend, a replay will be available starting at noon on February 9. STERIS is recognized for its infection prevention products and services aimed at supporting patient care.
STERIS plc (NYSE: STE) reported its fiscal 2023 second quarter results, showing revenue was flat at $1.2 billion year-over-year, with a 7% increase in constant currency organic revenue. The company incurred a net loss of $315.3 million, or ($3.15) per share, due to a $490.6 million impairment charge related to its Dental segment. Adjusted earnings per diluted share remained steady at $1.99. The company anticipates foreign currency headwinds affecting revenue growth, now expected to be 8%, down from 9%. Free cash flow projections decreased to $600 million from $675 million.
STERIS plc (NYSE: STE) has declared a quarterly interim dividend of $0.47 per share, which will be paid on December 16, 2022, to shareholders on record by November 22, 2022. This reinforces STERIS's commitment to shareholder returns while they continue to provide innovative healthcare solutions focusing on infection prevention. The company is a prominent player in enhancing patient care and safety globally.
STERIS plc (NYSE: STE) will host a conference call on November 10, 2022, at 10:00 a.m. ET to discuss its fiscal 2023 second quarter financial results. A press release with these results will be released after market close on November 9, 2022. Investors can join the call via the website or by phone. A replay will be available afterward. STERIS specializes in products and services that enhance patient care and infection prevention globally. For further details, visit www.steris.com.
STERIS plc (NYSE: STE) reported a strong performance in its fiscal 2023 first quarter, ending June 30, with a 19% increase in revenue to $1.2 billion compared to $968.4 million in Q1 fiscal 2022. Adjusted EPS was $1.90, up from $1.76 a year ago. The company noted significant growth in its Healthcare segment, with a 16% revenue rise driven by consumables and capital equipment. Despite challenges, STERIS projected a 10% organic revenue growth and adjusted EPS guidance of $8.40 to $8.60 for the fiscal year.
STERIS plc (NYSE: STE) has announced a quarterly interim dividend of $0.47 per share, marking a $0.04 increase. This is the Company's 17th consecutive year of dividend growth. The dividend will be payable on September 23, 2022, to shareholders on record as of September 7, 2022. STERIS is recognized as a leading global provider of products and services aimed at enhancing patient care, particularly focusing on infection prevention.
STERIS plc (NYSE: STE) will host a conference call on August 3, 2022, at 10:00 a.m. ET to discuss its fiscal 2023 first quarter financial results. A press release with detailed results will be issued after the U.S. market closes on August 2, 2022. Investors can access the live call via the company’s website or by phone. A replay of the call will be available starting at 12:00 p.m. ET on the same day. STERIS provides innovative healthcare products and services, focusing on infection prevention to promote a healthier world.
STERIS plc reported a 39% increase in fourth quarter revenue for fiscal 2022, reaching $1.2 billion compared to $873.5 million in the prior year. The adjusted EPS stood at $2.04, up from $1.63. Healthcare revenue rose 32%, aided by acquisitions, while Applied Sterilization Technologies and Life Sciences segments also showed strong growth. However, full-year net income decreased to $243.9 million or $2.48 per diluted share, affected by $654 million in acquisition-related expenses. Looking ahead, STERIS expects 11% organic revenue growth in FY2023.
STERIS plc (NYSE: STE) has announced a quarterly dividend of $0.43 per share, payable on June 28, 2022, to shareholders on record by June 14, 2022. This decision underscores STERIS's commitment to returning value to its shareholders while reinforcing its position as a leading provider of health products emphasizing infection prevention. The company's innovative offerings aim to contribute to a healthier world. For more details, visit www.steris.com.
STERIS plc (NYSE: STE) will host a conference call on May 12, 2022, at 10:00 a.m. ET to discuss its fiscal 2022 fourth quarter and full year financial results. A press release detailing these results will be issued following the market's close on May 11, 2022. Investors can access the live call via the company’s investor relations website or by phone. A replay will be available post-call. STERIS is known for providing innovative healthcare products and services focused on infection prevention.
FAQ
What is the current stock price of Steris Plc (STE)?
What is the market cap of Steris Plc (STE)?
